Works matching Bristol-Myers Squibb Company
Results: 1079
Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke<sup>®</sup> and Glucophage<sup>®</sup>-XR) in healthy Chinese volunteers: a randomized phase I clinical trial.
- Published in:
- Annals of Medicine, 2022, v. 54, n. 1, p. 2626, doi. 10.1080/07853890.2022.2125574
- By:
- Publication type:
- Article
Morphology Zosteriform skin metastases.
- Published in:
- International Journal of Dermatology, 2004, v. 43, n. 2, p. 126, doi. 10.1111/j.1365-4632.2004.02112.x
- By:
- Publication type:
- Article
256-OR: Substantial Cardiovascular Risk Reduction with Icosapent Ethyl Regardless of Diabetes Status or BMI: REDUCE-IT BMI.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-256-OR
- By:
- Publication type:
- Article
133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-133-LB
- By:
- Publication type:
- Article
129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-129-LB
- By:
- Publication type:
- Article
808-P: Economic Benefits of Initiating Empagliflozin vs. GLP-1 Receptor Agonists among Patients with Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-808-P
- By:
- Publication type:
- Article
796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-796-P
- By:
- Publication type:
- Article
791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-791-P
- By:
- Publication type:
- Article
788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-788-P
- By:
- Publication type:
- Article
786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-786-P
- By:
- Publication type:
- Article
785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-785-P
- By:
- Publication type:
- Article
783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-783-P
- By:
- Publication type:
- Article
17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-17-OR
- By:
- Publication type:
- Article
1644-P: Novel Subgroups of Prediabetes and Their Clinical Outcomes: A Data-Driven Analysis.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1644-P
- By:
- Publication type:
- Article
1566-P: Clinical Characteristics, Antihyperglycaemic Treatment Patterns, and Blood Glucose Control in Older Type 2 Diabetes Mellitus (T2DM) Patients in China: A Nationwide Cross-Sectional Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1566-P
- By:
- Publication type:
- Article
1521-P: An Efficacy Evaluation on Prediabetes Management Using a Machine Learning-Based Risk Stratification Approach.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1521-P
- By:
- Publication type:
- Article
1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1448-P
- By:
- Publication type:
- Article
137-LB: Safety Assessment of SAR341402 and NovoLog When Administered through an Insulin Pump.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-137-LB
- By:
- Publication type:
- Article
136-OR: Efficacy of Cenicriviroc (CVC) in Adults with NASH-Induced Liver Fibrosis.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-136-OR
- By:
- Publication type:
- Article
1231-P: Dapagliflozin (DAPA) in Type 1 Diabetes (T1D): Pooled Outcomes from DEPICT-1 and -2.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1231-P
- By:
- Publication type:
- Article
8-OR: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-8-OR
- By:
- Publication type:
- Article
1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1216-P
- By:
- Publication type:
- Article
1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1206-P
- By:
- Publication type:
- Article
467-P: Estimation of 10-Year Cardiovascular Risk among Newly Diagnosed Type 2 Diabetes Patients in the "Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China (NEW2D)" Study Population.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-467-P
- By:
- Publication type:
- Article
432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-432-P
- By:
- Publication type:
- Article
388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-388-P
- By:
- Publication type:
- Article
1164-P: Effects of Cenicriviroc in Adults with NASH on Inflammatory Cytokines and Metabolic Parameters.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1164-P
- By:
- Publication type:
- Article
297-LB: Dietary Fructose Increases Plasma Angiopoietin-Like Protein-3 Concentrations in Rhesus Macaques: Prevention with Fish Oil Supplementation.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-297-LB
- By:
- Publication type:
- Article
1148-P: Cenicriviroc Safety in over 1,200 Subjects.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1148-P
- By:
- Publication type:
- Article
1142-P: Efficacy and Safety of Antidiabetes Treatment in Adjunct to Insulin in Type 1 Diabetes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1142-P
- By:
- Publication type:
- Article
244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-244-OR
- By:
- Publication type:
- Article
236-OR: Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-236-OR
- By:
- Publication type:
- Article
2301-PUB: Efficacy of HbA1c Changes, Weight Changes, and Blood Pressure Changes in GLP-1RA Daily Treatment or GLP-1RA Weekly Treatment in Type 2 Diabetes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-2301-PUB
- By:
- Publication type:
- Article
2100-P: The Association between Blood Glucose and Different Anthropometrics and Body Composition Measures in the Chinese Population: Results from the Pinggu Metabolic Disease Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-2100-P
- By:
- Publication type:
- Article
207-LB: Type 2 Diabetes and Heart Failure: Insights from the DISCOVER Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-207-LB
- By:
- Publication type:
- Article
1102-P: High vs. Standard Starting Dose of Insulin Glargine 100 U/ml in Patients with Overweight/Obesity and Type 2 Diabetes Uncontrolled with Oral Antidiabetic Drugs in China: A Multicenter, Open-Label Randomized Controlled Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1102-P
- By:
- Publication type:
- Article
1093-P: The Prevalence and Clinical Characteristics of Insulin Antibody Formation in Patients with Type 2 Diabetes Treated with Insulin.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1093-P
- By:
- Publication type:
- Article
18-OR: Efficacy and Safety of Chiglitazar vs. Sitagliptin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Noninferiority Phase 3 Trial (CMAS).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-18-OR
- By:
- Publication type:
- Article
1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1876-P
- By:
- Publication type:
- Article
1856-P: A High Sugar (Fructose) Diet Increases C-Reactive Protein (CRP) in Rhesus Macaques: Relationships with Changes of Apolipoproteins and Adiponectin.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1856-P
- By:
- Publication type:
- Article
1080-P: A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing Patient Satisfaction and Compliance with a Needle-Free Insulin Injector vs. Conventional Insulin Pen Injections in Chinese Patients with Type 2 Diabetes Mellitus
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1080-P
- By:
- Publication type:
- Article
1072-P: Comparison of the Efficacy between a Needle-Free Insulin Injector and Conventional Insulin Pen in Glycemic Control in Insulin-treated Type 2 Diabetic Patients in China.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1072-P
- By:
- Publication type:
- Article
1068-P: A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Safety Profile of a Needle-Free Insulin Injector with Conventional Insulin Pen Injections in Chinese Patients with Type 2 Diabetes Mellitus.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1068-P
- By:
- Publication type:
- Article
1026-P: Dipeptidyl Peptidase-4 Inhibitor Treatment and the Risk of Bullous Pemphigoid and Other Skin-Related Adverse Events: A Meta-analysis.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1026-P
- By:
- Publication type:
- Article
Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism.
- Published in:
- Drug Metabolism Reviews, 2010, v. 42, n. 1, p. 53, doi. 10.3109/03602530903209395
- By:
- Publication type:
- Article
Hedgehog Drugs Begin To Show Results.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 10, p. 692, doi. 10.1093/jnci/djn169
- By:
- Publication type:
- Article
The worst of times, the best of times.
- Published in:
- 2009
- Publication type:
- Editorial
In their words.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 10, p. 1061
- Publication type:
- Article
Research collaborations.
- Published in:
- Nature Biotechnology, 1999, v. 17, n. 12, p. 1148
- Publication type:
- Article
New type 2 diabetes drug encourages weight loss.
- Published in:
- Podiatry Now, 2013, v. 16, n. 2, p. 13
- Publication type:
- Article